A Case of Acute Kidney Injury with Marked Hyperuricemia During Mizoribine Administration

DOI 機関リポジトリ HANDLE Web Site PubMed
  • Nishino Tomoya
    Second Department of Internal Medicine, Nagasaki University of Medicine, Japan
  • Shinzato Takeaki
    Department of Nephrology, Sasebo General Hospital, Japan
  • Ohta Yuuki
    Department of Nephrology, Sasebo General Hospital, Japan
  • Yamashita Hiroshi
    Department of Nephrology, Sasebo General Hospital, Japan
  • Obata Yoko
    Second Department of Internal Medicine, Nagasaki University of Medicine, Japan
  • Shinzato Ken
    Shinzato Clinic Urakami, Japan
  • Kohno Shigeru
    Second Department of Internal Medicine, Nagasaki University of Medicine, Japan

この論文をさがす

抄録

A 52-year-old woman was diagnosed with Blau syndrome and rheumatoid arthritis and was treated with prednisolone and methotrexate. Joint pain and skin ulcers were poorly controlled; therefore, mizoribine (MZ; 150 mg/day) was administered once daily from March 2011. In early July 2011, the patient was hospitalized because of acute kidney injury (AKI) and acute pancreatitis. We reasoned that AKI resulted from hyperuricemia during MZ administration because serum concentrations of uric acid (31.6 mg/dL) and MZ (trough level, 5.14 μg/mL) were markedly elevated on admission. MZ should be administered with caution because of the risk of marked hyperuricemia leading to AKI.<br>

収録刊行物

  • Internal Medicine

    Internal Medicine 51 (10), 1239-1243, 2012

    一般社団法人 日本内科学会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ